-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lift our 12-month target to $142 from $136, reflecting 15x our FY 26 EPS of $9.51 (up from $8.48; FY 27 EPS raised to $10.20 from $9.62). This multiple exceeds the long-term mean of 12x but aligns more closely with the peer average, which we believe is justified as BG emerges as a more diversified global player following the Viterra acquisition. Expectations were elevated heading into this release, particularly after recent favorable U.S. biofuel policy rules. This policy momentum is expanding globally, with Brazil, Indonesia, and Europe moving toward greater biofuel utilization, partly due to elevated crude oil prices stemming from Middle East tensions. We view the company's updated EPS outlook ($9.00 to $9.50 from $7.50 to $8.00) favorably and see further upside potential if forward crush margins improve in 2H 26 (current curves reflect heightened uncertainty in the back half of the year).